Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Emerging biomarkers for PD-1 pathway cancer therapy.
Lim JS, Sundar R, Chénard-Poirier M, Lopez J, Yap TA. Lim JS, et al. Among authors: lopez j. Biomark Med. 2017 Jan;11(1):53-67. doi: 10.2217/bmm-2016-0228. Epub 2016 Dec 12. Biomark Med. 2017. PMID: 27936870 Review.
Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors.
Ameratunga M, Chénard-Poirier M, Moreno Candilejo I, Pedregal M, Lui A, Dolling D, Aversa C, Ingles Garces A, Ang JE, Banerji U, Kaye S, Gan H, Doger B, Moreno V, de Bono J, Lopez J. Ameratunga M, et al. Eur J Cancer. 2018 Jan;89:56-63. doi: 10.1016/j.ejca.2017.11.012. Epub 2017 Dec 8. Eur J Cancer. 2018. PMID: 29227818 Clinical Trial.
Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials.
Sundar R, McVeigh T, Dolling D, Petruckevitch A, Diamantis N, Ang JE, Chenard-Poiriér M, Collins D, Lim J, Ameratunga M, Khan K, Kaye SB, Banerji U, Lopez J, George AJ, de Bono JS, van der Graaf WT. Sundar R, et al. Among authors: lopez j. Eur J Cancer. 2018 Sep;101:55-61. doi: 10.1016/j.ejca.2018.06.003. Epub 2018 Jul 17. Eur J Cancer. 2018. PMID: 30025230 Free article. Clinical Trial.
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.
Guo C, Chénard-Poirier M, Roda D, de Miguel M, Harris SJ, Candilejo IM, Sriskandarajah P, Xu W, Scaranti M, Constantinidou A, King J, Parmar M, Turner AJ, Carreira S, Riisnaes R, Finneran L, Hall E, Ishikawa Y, Nakai K, Tunariu N, Basu B, Kaiser M, Lopez JS, Minchom A, de Bono JS, Banerji U. Guo C, et al. Among authors: lopez js. Lancet Oncol. 2020 Nov;21(11):1478-1488. doi: 10.1016/S1470-2045(20)30464-2. Epub 2020 Oct 28. Lancet Oncol. 2020. PMID: 33128873 Clinical Trial.
131 results